The Effects of Withdrawing the Alpha-1 Blocker from Alpha-1 Blocker plus 5-Alpha-Reductase Inhibitor Combination Therapy on Patients with Benign Prostatic Hyperplasia from the Perspective of Urodynamics Study

Trial Profile

The Effects of Withdrawing the Alpha-1 Blocker from Alpha-1 Blocker plus 5-Alpha-Reductase Inhibitor Combination Therapy on Patients with Benign Prostatic Hyperplasia from the Perspective of Urodynamics Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Dutasteride (Primary) ; Silodosin
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2015 New trial record
    • 09 Oct 2015 Results presented at the 45th Annual Meeting of the International Continence Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top